Promising Outlook for Oric Pharmaceuticals: Buy Rating Backed by Prostate Cancer Program Developments and Strong Financial Position

Analyst Soumit Roy of JonesTrading reiterated a Buy rating on Oric Pharmaceuticals, boosting the price target to $20.00.

Soumit Roy has given his Buy rating due to a combination of factors surrounding Oric Pharmaceuticals’ promising developments in their prostate cancer program. The upcoming data updates in the fourth quarter of 2025 and the first quarter of 2026 are expected to provide significant insights into dose optimization and efficacy of their treatment, ORIC-944, particularly in combination with other therapies like apalutamide or darolutamide.
The anticipated data will focus on response rates, safety, and potential long-term benefits, with early results showing promising efficacy and safety profiles compared to competitors like Pfizer’s mevrometostat. Additionally, the company’s financial position, with substantial cash reserves, supports ongoing research and development efforts, reinforcing the positive outlook for ORIC’s stock.